Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Pfizer
Northwestern University
Fondazione Michelangelo
University of Miami
Barbara Ann Karmanos Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Northside Hospital, Inc.
Rutgers, The State University of New Jersey